Cargando…

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA(1c) Levels

IMPORTANCE: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy has been associated with cardiovascular benefits and a few adverse events; however, whether the comparative effectiveness and safety profiles vary with differences in baseline hemoglobin A(1c) (HbA(1c)) levels is unknown. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Andrea, Elvira, Wexler, Deborah J., Kim, Seoyoung C., Paik, Julie M., Alt, Ethan, Patorno, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989905/ https://www.ncbi.nlm.nih.gov/pubmed/36745425 http://dx.doi.org/10.1001/jamainternmed.2022.6664

Ejemplares similares

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
por: Zhuo, Min, et al.
Publicado: (2022)

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
por: Kaze, Arnaud D., et al.
Publicado: (2022)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

DPP-4 inhibitor treatment: β-cell response but not HbA(1c) reduction is dependent on the duration of diabetes
por: Kozlovski, Plamen, et al.
Publicado: (2017)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
por: Zhuo, Min, et al.
Publicado: (2021)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
por: Cha, Seon-Ah, et al.
Publicado: (2017)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2012)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
por: Foley, James E, et al.
Publicado: (2016)

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND SULFONYLUREA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Pawar, Ajinkya, et al.
Publicado: (2019)

Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
por: Gentilella, Raffaella, et al.
Publicado: (2019)

A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
por: Esposito, Katherine, et al.
Publicado: (2015)

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
por: Jones, Angus G., et al.
Publicado: (2016)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA(1C) in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study
por: Kim, So Ra, et al.
Publicado: (2017)

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
por: Chanawong, Apichaya, et al.
Publicado: (2023)

Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis
por: He, Lingyu, et al.
Publicado: (2016)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
por: Gonzalez, Jimmy, et al.
Publicado: (2023)

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
por: Kim, Kyuho, et al.
Publicado: (2021)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p1n3f6bvlreosq14p44mt47s8u